Line of abiraterone acetate in castration-resistant metastatic prostate cancer-Does it matter? report of a multi-institutional experience

Indian Journal of Cancer

Volumn 52, Issue 4, 2015, Pages 658-660

  Gunduz, S ^a   Bozcuk, H ^a   Yildiz, M ^b   Goksu, S ^a   Uysal, M ^c   Arslan, D ^a   Tatli, A M ^a   Mutlu, H ^a   Coskun, H S ^a   Ozdogan, M ^d  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Antalya Research and Practice Hospital ^*  (Turkey)

^c AFYON KOCATEPE UNIVERSITY   (Turkey)

^d Memorial Health Group   (Turkey)

Author keywords

Abiraterone; cabazitaxel; castration resistant prostatate cancer

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; ABIRATERONE; ANDROSTANE DERIVATIVE;

ADULT; AGED; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE STUDY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TURKEY (REPUBLIC); VISCERAL METASTASIS; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84961970515     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.178379     Document Type: Conference Paper

References (14)

1. Siegel R., Naishadham D. and Jemal A. Cancer Statistics, 2013; CA Cancer J Clin 2013: 63: 11-30.
2. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009;27:5431-8.
3. Pinto A. Beyond abiraterone: New hormonal therapies for metastatic castration-resistant prostate cancer Cancer Biol Ther. 2013 Oct 7;15 (2).
4. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368 (2):138-48.
5. Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: Inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011;185:787-94.
6. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
7. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
8. Rathkopf DE, Smith MR, De Bono JS, Logothetis CJ, Shore ND, de SouzaP et al. Long-term safety and efficacy analysis of abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer without prior chemotherapy (COU-AA-302). J Clin Oncol 2013; 31:15. [ASCO Annual Meeting Abstracts].
9. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376:1147-54.
10. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare benefi ciaries, 1999-2006. Prostate Cancer Prostatic Dis 2011; 14:177-83.
11. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 Dec; 13 (12):1210-7.
12. Garcia JA, Rini BI. Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead. Cancer. 2012 May 15;118 (10):2583-93.
13. L. Albiges, S. Le Moulec, Y. Loriot, et al. Reponse to cabazitaxel in the postchemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate Annals of Oncology 2012; 23 (Supplement 9): 9294-9318.
14. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983-92.